Leo Wealth LLC Has $35.18 Million Stock Holdings in Johnson & Johnson $JNJ

Leo Wealth LLC lifted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 3.4% in the fourth quarter, HoldingsChannel reports. The fund owned 170,004 shares of the company’s stock after acquiring an additional 5,585 shares during the period. Johnson & Johnson makes up approximately 2.6% of Leo Wealth LLC’s holdings, making the stock its 7th largest holding. Leo Wealth LLC’s holdings in Johnson & Johnson were worth $35,182,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in JNJ. Capital International Investors lifted its position in shares of Johnson & Johnson by 545.6% in the third quarter. Capital International Investors now owns 3,865,050 shares of the company’s stock valued at $716,657,000 after acquiring an additional 3,266,354 shares in the last quarter. Amundi lifted its position in shares of Johnson & Johnson by 19.3% in the third quarter. Amundi now owns 13,354,936 shares of the company’s stock valued at $2,512,719,000 after acquiring an additional 2,163,838 shares in the last quarter. Marshall Wace LLP lifted its position in shares of Johnson & Johnson by 126.3% in the third quarter. Marshall Wace LLP now owns 3,584,162 shares of the company’s stock valued at $664,575,000 after acquiring an additional 2,000,609 shares in the last quarter. Danske Bank A S purchased a new position in shares of Johnson & Johnson in the third quarter valued at about $367,467,000. Finally, Wellington Management Group LLP lifted its position in shares of Johnson & Johnson by 3.8% in the third quarter. Wellington Management Group LLP now owns 25,832,777 shares of the company’s stock valued at $4,789,914,000 after acquiring an additional 956,239 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors.

Key Stories Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Big analyst bullishness — Citigroup raised its price target to $285 and maintained a Buy, signaling a material upside to consensus; Guggenheim and TD Cowen also have Buy calls and lifted targets, supporting near-term demand. Citigroup raises price target to $285
• Positive Sentiment: New/maintained buy coverage from TD Cowen and supportive analyst commentary highlight J&J’s diversified pipeline and attractive risk/reward into earnings. TD Cowen / TipRanks coverage
• Positive Sentiment: Regulatory / product catalyst — J&J launched its next‑gen Varipulse Pro PFA catheter in Europe (CE mark), which could support device revenue growth in electrophysiology. Varipulse Pro launch in Europe
• Positive Sentiment: Specialty therapy wins — permanent U.S. reimbursement code for bladder cancer therapy INLEXZO and distribution deals (e.g., SIRTURO in Japan) reduce commercialization risk and boost revenue visibility in niche franchises. Johnson & Johnson updates key specialty therapies
• Neutral Sentiment: Media/analyst pieces are bullish ahead of Q1 — Barron’s and other outlets recommend buying into the earnings run-up, which supports momentum but also raises expectations risk. Barron’s: Buy ahead of earnings
• Neutral Sentiment: Mixed market commentary — coverage noting the stock “increases yet falls behind the market” and inclusion on low‑volatility/blue‑chip lists boost interest but are not direct fundamental drivers. Zacks: Increases yet falls behind market

Johnson & Johnson Price Performance

NYSE:JNJ opened at $241.01 on Thursday. The company has a current ratio of 1.03, a quick ratio of 0.77 and a debt-to-equity ratio of 0.48. The company has a market capitalization of $580.51 billion, a P/E ratio of 21.81, a P/E/G ratio of 2.41 and a beta of 0.34. Johnson & Johnson has a 12 month low of $141.50 and a 12 month high of $251.71. The business’s 50-day moving average is $240.79 and its 200 day moving average is $214.35.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Saturday, January 31st. The company reported $2.46 EPS for the quarter. The company had revenue of $24.28 billion for the quarter. Johnson & Johnson had a return on equity of 33.04% and a net margin of 28.46%. On average, equities research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Timothy Schmid sold 1,322 shares of the business’s stock in a transaction that occurred on Friday, February 20th. The stock was sold at an average price of $245.66, for a total transaction of $324,762.52. Following the sale, the executive vice president directly owned 25,447 shares of the company’s stock, valued at $6,251,310.02. The trade was a 4.94% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Vanessa Broadhurst sold 6,197 shares of the business’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total value of $1,508,287.83. Following the sale, the executive vice president directly owned 23,003 shares in the company, valued at $5,598,700.17. The trade was a 21.22% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 30,142 shares of company stock worth $7,360,528 over the last quarter. 0.16% of the stock is owned by company insiders.

Analyst Ratings Changes

Several brokerages have recently commented on JNJ. Rothschild & Co Redburn boosted their price objective on Johnson & Johnson from $180.00 to $210.00 and gave the company a “neutral” rating in a research report on Thursday, February 19th. Citigroup boosted their price objective on Johnson & Johnson from $274.00 to $285.00 and gave the company a “buy” rating in a research report on Tuesday. Weiss Ratings restated a “buy (b)” rating on shares of Johnson & Johnson in a research report on Wednesday, January 28th. UBS Group restated a “buy” rating on shares of Johnson & Johnson in a research report on Monday, January 5th. Finally, Argus boosted their price objective on Johnson & Johnson from $210.00 to $240.00 in a research report on Friday, January 23rd. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $237.57.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.